Third time’s the charm: Purdue sues again for OxyContin patent

For the third time in two months, Purdue Pharma is suing the makers of a generic version of OxyContin over patent rights. According to this article from the Economic Times, Purdue filed suit against India’s Ranbaxy Laboratories for its low-cost version of the opioid painkiller. Purdue currently holds exclusive rights on its $3 billion-per-year patent for OxyContin, which expires in April 2013, and has been notoriously litigious in protecting that exclusivity.

Read more about Purdue’s recent suits against Watson Pharmaceuticals and Impax Laboratories.

About Dana Owens

Dana Owens is San Francisco-based writer, editor and blogger who works on diverse projects from holistic health research to record label promotion. In addition to lending her editorial eye to Oxy Watchdog, Dana also acts as copyeditor for 99 Series, Inc. and executive assistant/project coordinator for Heartline Productions.
This entry was posted in Pharmaceutical Industry and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *